GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Makes a Stem Cell Success Rate Credible?

A stem cell success rate is credible when you can trace it to a report that tells you who was treated, which cell product they received and how, what counted as success, when it was measured, and who was included in the calculation. There is no single success rate for stem cell therapy. Even a well-reported percentage may not apply to your condition or tell you how much the treatment helped compared with other care.

Read the study behind the number

Take the FDA prescribing information for Ryoncil, an intravenous therapy made from donor bone marrow–derived mesenchymal stromal cells. In the United States, it is approved for patients aged 2 months and older with acute graft-versus-host disease that does not respond to steroids. The study enrolled children with grade B to D disease after a donor blood-forming stem cell transplant, excluding grade B disease limited to the skin. Of 55 children enrolled, 54 received Ryoncil and were included in the efficacy analysis. The initial course was eight infusions over four weeks [1].

What Makes a Stem Cell Success Rate Credible?

To check the headline figure, go to Table 4 in the prescribing information: at day 28, 38 of 54 treated children had responded (70%; 95% confidence interval, 56.4% to 82.0%). Sixteen had a complete response, meaning the disease resolved in all affected organs. Twenty-two had a partial response, meaning at least one organ improved by one stage or more without another worsening. The percentages for complete and partial response were rounded separately, so they add to 71%, even though the overall response rounds to 70% [1].

The trial registry describes this as a phase 3 study, but it had no comparison group [2]. The 70% tells you what was observed in the treated group, not how much better Ryoncil worked than another treatment or what to expect from a different cell product.

Check whether the treatment matches yours

Match the diagnosis and stage, the source and type of cells, the dose and number of sessions, and how the cells are given. For example, a blood-forming stem cell transplant used in cancer care can restore blood cell production after high-dose chemotherapy or radiation. Its results do not tell you whether an injection into the knee will ease pain or improve walking [3]. If a clinic says it uses your own cells or donor cells, the guide to autologous and allogeneic cells explains those terms. For a knee claim, ask what counted as improvement: less pain, better function, or both, and by how much.

Count who was left out

Suppose 100 people start treatment, only 10 are assessed at the advertised follow-up, and 9 improve. That is 90% of the 10 assessed, but only 9 of the original 100 are known to have improved. The other 90 outcomes are unknown: 9% is the share with documented improvement, not the true improvement rate. Ask how many people started, how many were assessed, why outcomes were missing, and how the analysis handled them. Testimonials cannot supply those answers [4].

Look for a fair comparison

A before-and-after result cannot separate the effect of the cells from other care or changes over time. In a well-designed randomized trial, people are assigned to groups by chance, which helps make the groups comparable [5]. Ask what the comparison group received and how many people in each group improved on the same measure at the same visit. A study without a comparison group can still report a response accurately; it cannot directly measure the added benefit over another option.

Check how long benefits lasted and what harms occurred

A day-28 response is not a cure. Among the day-28 Ryoncil responders, the reported median response duration was 54 days, measured from that response assessment to disease progression, a new systemic treatment for acute graft-versus-host disease, or death from any cause. Common adverse reactions included infections, fever, bleeding, swelling, abdominal pain, and high blood pressure [1].

Ask how many people were still being followed at later visits and how often serious harms occurred. The FDA has warned about reports of blindness, tumors, and infections in connection with unapproved regenerative medicine products in the United States [6]. That warning does not give a risk rate for a specific procedure. If you are considering care abroad, use these safety questions for treatment in Japan to plan who to contact if a complication occurs after you go home.

Separate approval from filing and trial registration

Japan regulates regenerative medicine practice and research under the Act on the Safety of Regenerative Medicine and the marketing of regenerative medical products under a separate law, the PMD Act [7]. Japan’s health ministry describes separate filing procedures for providing regenerative medicine as research and outside research [8]. A clinic’s provision-plan filing is not marketing approval and does not establish that the procedure works. Ask whether the offer is a service outside a study, whether the exact product is approved for the proposed use, and what human results support it. The guide to Japan’s registration and compliance process provides background on the paperwork.

If you are offered a place in a study, ask for its registry ID and look for posted results or a published report. A ClinicalTrials.gov listing does not mean the U.S. government has evaluated the study’s safety or scientific validity, and registration is not evidence that the treatment works [9].

What to ask before paying or traveling

Checklist for a quoted stem cell success rate
What to checkWhat to ask for
Treatment matchThe diagnosis, stage, cell product, dose, and route studied.
Outcome and timingThe definition of success, the visit date, and any later results.
Patient countsThe numbers treated, assessed, and improved, plus how missing outcomes were handled.
ComparisonResults for both groups, or confirmation that there was no comparison group.
Harms and aftercareHow often complications occurred, how serious they were, and who handles follow-up.
Regulatory statusWhether the exact use is approved and whether the offer is part of a study.

Ask for the original report and the page or table the rate came from, not just a brochure. If you are planning care in Japan, the guide to the treatment process in Japan can help you organize questions about consent, costs, and follow-up.

If you cannot verify where a percentage came from or whether it applies to the same condition and treatment, do not use it as your personal odds of success. Review the evidence, risks, and alternatives with your treating clinician before making a decision.

Planning a consultation in Japan?

Use the inquiry page for appointment and logistics questions. Bring any quoted rate and its source to your treating clinician.

Ask about appointments

This article is general information, not medical advice.